Bio
Since 2010, X2 Biosystems has pioneered the development of wearable impact monitoring devices and neurocognitive assessment solutions proven to significantly reduce the risks, incidence, and costs of concussions in athletic and military environments. John joined X2 as CEO in November 2014, bringing 25+ years of experience spanning R&D, sales, marketing, and CEO in a diverse set of industries that have all become X2 enablers, including system-on-chip technologies, wireless communications, enterprise and consumer mobile applications, software-as-a-service (SaaS) platforms, and big data/analytics for the medical and smart grid industries. John earned B.Sc. degrees in Physics and Electrical Engineering from MIT, a Ph.D. in Electrical Engineering from Cornell University, and the M.Sc. in Management of Technology from MIT’s Sloan School of Management. He is the proud father of three children who, between soccer, lacrosse, hockey, skiing, basketball, and baseball, have had their share of frightening bangs on the head.
Sessions
-
How Wearables are Helping to Monitor and Manage Head Impact Risks in Sports09:55 AM - 10:15 AM Jun 1The ability to directly monitor head impact biomechanics using wearable sensors has fundamentally changed our understanding of the corresponding risks in a wide range of sports. One key finding is that significant tissue damage and changes in neural connectivity may result even in the absence of clinically diagnosed concussion symptoms. We will discuss our recent advances in evolving wearable sensors into advanced neuro-trauma dosimeters, suitable for monitoring cumulative damage due to repetitive head impacts and developing remove-from-play thresholds. These efforts combine measured head impact biomechanics, finite element modeling of the corresponding forces generated in the brain, and high resolution MRI imaging of the resulting changes in neural connectivity. We will also discuss related applications of wearable head impact sensors in the development of new concussion diagnostics such as blood biomarkers and eye tracking.